By Dr. Rohan Mahajan, DM Gastroenterology, Mahajan Hospital.
The need for better liver assessment is particularly relevant today because of the rapid increase in obesity, diabetes and metabolic disease. According to the World Health Organization, 1.1 billion people worldwide were living with obesity in 2024. Obesity is also increasingly linked with metabolic diseases affecting the liver. FibroScan has become an important tool in modern liver care.
The important point is that the amount of fat and the amount of scar tissue are not the same thing. A person may have a very fatty liver without advanced fibrosis, while another person with relatively modest fatty change may already have significant scarring.
That is where FibroScan becomes particularly useful.
FibroScan uses a technology called transient elastography to assess the physical stiffness of the liver. Liver stiffness is measured in kilopascals (kPa) and can provide an estimate of the likelihood of significant fibrosis.
Modern FibroScan examinations can also provide a Controlled Attenuation Parameter (CAP), which estimates the amount of fat in the liver. In other words, the test can provide information about two important components of liver disease-fat and fibrosis.
ALT and AST are useful blood tests, but they do not directly measure liver fibrosis. A person can have significant liver disease even when these enzymes are not markedly elevated.
FibroScan offers a different piece of information: how stiff the liver is.
International liver guidelines recognise transient elastography and other non-invasive tests as valuable tools for identifying people at risk of advanced fibrosis and helping determine who needs further specialist assessment.
One of the biggest advantages of FibroScan is its simplicity.
The patient lies down, and a probe is placed over the right upper abdomen. The machine sends painless vibrations through the liver and measures how quickly the resulting waves travel through the tissue.
There is no needle, no biopsy and generally no recovery period.
This makes FibroScan particularly attractive for monitoring chronic liver diseases over time. Unlike a biopsy, which samples only a small piece of liver, a non-invasive test can be repeated when clinically appropriate.
It can be particularly useful in people with:
Importantly, FibroScan should not be treated as a standalone diagnosis. Its results need to be interpreted alongside medical history, examination, blood tests and imaging. Factors such as active liver inflammation, congestion and obesity can affect measurements, and sometimes additional testing is required.
Perhaps the greatest advantage of FibroScan is not diagnosing a disease that is already obvious-it is helping identify silent liver damage in people who feel completely healthy.
And this is an important message: losing weight is not only about looking better-it can also mean protecting the liver.
The goal is not to replace every other liver investigation. Rather, FibroScan is part of a stepwise, non-invasive approach to identifying people at risk of advanced liver disease.
Fatty liver is increasingly becoming a metabolic health issue rather than simply a liver problem. With obesity and diabetes rising worldwide, identifying people who have progressed from fat accumulation to fibrosis is becoming increasingly important.
A normal blood report does not always mean a healthy liver. And a fatty liver does not automatically mean cirrhosis.
FibroScan helps bridge that gap-quickly, painlessly and without a needle-allowing doctors to look beyond routine blood tests and better understand the condition of the liver.
Your liver may not hurt when it is getting damaged. Sometimes, the smartest approach is to check before it starts hurting.
Mahajan Hospital
Address - A4, Uttam Nagar, New Delhi
Mob No. 9871100201
Instagram - yourindianguy
